newsfilter
← Earnings
Earnings Releases·

Absci Corporation — Third Quarter 2026 Earnings Summary

  • Revenue declined 25% year-over-year to $0.3 million, while R&D expenses rose 23% to $23.6 million and net loss widened to $33.3 million from $28.7 million in the prior year period.
  • Cash and marketable securities decreased to $173.7 million as of September 30, 2026, though management projects these funds will support operations through the second half of 2028.
  • Clinical milestones include anticipated 13-week interim proof-of-concept data for the ABS-201 HEADLINE trial in December 2026, with full 26-week data expected in early 2027 and Phase 2 STORYLINE trial initiation planned for mid-2027.
  • Strategic commercial infrastructure was strengthened by the appointment of Gerry Muhle as Chief Commercial Officer to support the launch of ABS-201 for pattern hair loss and endometriosis.
Company
ABSCI CORP
Sector
Healthcare
Industry
Biotechnology